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Abstract
Purpose Multimodal preoperative evaluation (MPE) is a
novel strategy for surgical decision making, incorporating
the transrectal ultrasound (TRUS), 64 multi-slice spiral
computer tomography (MSCT), and serum amyloid A
protein (SAA) for rectal cancer. This trial aims to determine
the accuracy of MPE in preoperative staging and its role in
surgical decision making for rectal cancer.
Methods Two hundred twenty-five participants with
histologically proven rectal cancer with tumor height
less than 10 cm were randomly assigned into three arms
in the ratio 1:1:1. Arm A (MPE) was multimodal staged
by the combination of MSCT, TRUS, and SAA. Arm B
(MSCT+SAA) was staged by MSCT and SAA. Arm C
(MSCT) was staged only by MSCT. The primary
endpoints were the accuracy of preoperative staging and
expected surgical procedures. This study is registered as
an International Standard Randomised Controlled Trial,
number ChiCTR-DT-00000409.
Results The analysis showed statistical difference in the
accuracy of T staging between arm A and B (94.6% vs.
77.8%, P=0.003) and arm A and C (94.6% vs. 80.6%, P=
0.010). Statistical difference was also observed between the
accuracies of preoperative N staging between arm A and C
(85.1% vs. 69.4%, P=0.023) and arm A and B (85.1% vs.
84.7%, P=0.029). Surgical decision making in arm A was
more accurate than that in arm C (95.9% vs. 80.6%, P=
0.001). Pathological T stage (P<0.001), N stage (P<0.001),
tumor node metastasis stage (P<0.001), serum level of SAA
(P=0.002), and tumor height (P=0.030) were significantly
associated with final surgical procedures.
Conclusion MPE is an effective strategy in preoperative
staging and more accurate than other available strategies in
surgical decision making for rectal cancer.
Keywords Rectal cancer . Surgical procedures .Multi-slice
spiral computer tomography . Transrectal ultrasound . Serum
amyloid A protein .Multimodal preoperative evaluation
Introduction
Preoperative evaluation of rectal carcinoma is crucial in the
decision making of preoperative treatment and surgical
procedures. All the choices of surgical procedures, e.g.,
extended surgery or local excision for rectal cancer, should
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be tailored on the basis of accurate preoperative staging [1–4].
Recently, the evidence-based move to selective preoperative
chemoradiotherapy for selected patients has intensified the
need to develop accurate image-based staging systems [5].
Additionally, the use of preoperative therapies may have
dramatic effects on the consequential pathological findings.
Therefore, accurate details prior to treatment are essential [6].
Various staging modalities for rectal cancer include
transrectal ultrasound (TRUS), computed tomography
(CT), and MR imaging (MRI) with or without endorectal
coil. Current evidence shows that TRUS is the most
established and preferred modality for T staging of rectal
cancer [7]; however, no ideal imaging technique is
available for evaluation of metastatic lymph nodes [8].
The multidetector CT is still the first option for distant
metastatic diseases [9].
Serum amyloid A protein (SAA), also termed as acute
phase protein, is a major factor in altering high-density
lipoproteins metabolism during inflammation [10]. Glojnaric
et al. [11] reported a significant increase of SAA level in
patients with colorectal cancer. More recent study showed
that an increased SAA level was associated with metastatic
lymph nodes in rectal cancer, which indicated the potential
value for preoperatively noninvasive identification of lymph
nodes [12]. Our previous study confirmed that the preoper-
ative evaluation strategy combining 64 multi-slice spiral
computer tomography (MSCT) with SAA improved the
accuracy of preoperative staging, particularly in N staging.
This strategy was more useful in planning the surgical
resection than MSCT alone as well [13].
In this prospective, randomized, and controlled study,
the multimodal preoperative evaluation (MPE) system was
set for surgical decision making in rectal cancer, incorpo-
rating TRUS, MSCT, and SAA. The MPE system uses
TRUS for T staging, MSCT for M staging, and assesses N
stage based on MSCT with SAA for identification. This
trial aims to determine the accuracy of MPE in preoperative
staging and its role in surgical decision making for rectal
cancer. In order to clarify the role of MPE in surgical
decision making, this trial is designed as a randomized
controlled study.
Materials and methods
All the study subjects were proven to be histologically
confirmed colorectal cancer patients. Eligibility criteria
included tumor height (proximal from dentate line) less
than 10 cm assessed by colonoscopy, tumor which can be
passed completely during colonoscopy, and operable dis-
eases. Exclusion criteria included patients with a history of
infection within the previous 1 month; immune system
disease history; and inflammatory bowel disease, bowel
obstruction, or a history of chronic diarrhea; and a neo-
adjuvant treatment history.
This was a prospective, single-center, randomized trial
conducted between July 2008 and March 2009. Patients
were randomly assigned into three arms in the ratio 1:1:1
done by a computer-generated randomization list. Conceal-
ment of treatment allocation was achieved with the use of
sealed opaque envelops each containing a unique study
number and prepared independently by a secretary.
Three arms were compared, each with a different workup
of technique for preoperative staging. Arm A (n=75) was
multimodal staged by the combination of MSCT, TRUS, and
SAA. Arm B (n=75) was staged by MSCT and SAA. Arm C
(n=75) was the control group, staged only by MSCT.
MSCT examinations were performed for all patients in
three arms by using a Philips Brilliance 64-slice CT scanner
(Philips Medical Systems, Best, The Netherlands). Before
MSCT examination, all patients were prepared with laxative
and enema. Sufflation of approximately 100 ml of air into
the rectum was performed, and sequences were obtained
with one breath-hold from the level of the diaphragm to the
anus in approximately 10 s. The slice interval was adjusted
to 5 mm. Imaging of MDCT was obtained using multi-
planar reformation technique. Enhancement medium
(Omnipaque: GE Healthcare, Buckinghamshire, United
Kingdom) was administered intravenously for all patients.
Computed tomography was prospectively evaluated prior to
surgery by one radiologist (Junhua Wu). The reader was
blinded to any patient information. The CT scans were
assessed for the depth of tumor invasion and the presence
of regional lymph node metastases. CT-tumor node metas-
tasis (TNM) stage was performed according to the Thoeni’s
classification (Table 1) [14]. Metastatic lymph nodes were
considered to be present if their diameter exceeded 8 mm.
TRUS was performed for arm A by using a Philips HDI
5000 ultrasound scanner (Philips Medical Systems, Bothell,
WA, USA). The rectal probe measures 16 cm in length with a
head diameter of 21 mm. During the examination, the
frequency can be switched from 7.5 MHz to 5 MHz with a
maximum tissue penetration of approximately 7 cm for the
latter. The beams can be emitted in line with or transverse to
the longitudinal axis of the rectum. TRUS was prospectively
evaluated prior to surgery by one ultrasonologist (Yingyu
Shi) who have more than 5-year experience on TRUS. The
reader was blinded to any patient information. The TRUS
scans were assessed for the depth of tumor invasion
following Hildenbrandt’s principles (Table 1) [15].
Venous blood specimens in arm A and B were taken on the
third day before surgery and sent to Clinical Immunology
Laboratory for test. SAA concentration was measured by
immunofixed time nephelometry (Dade Behring Diagnostics).
The serum SAA level was measured according to the
manufacturer’s instructions. In the meantime, venous blood
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samples were also submitted to Clinical Blood Laboratory for
a blood routine test in order to exclude inflammatory cases.
Surgeons collected the information of preoperative
evaluation and performed the preoperative staging according
to Table 1 [13]. Two senior surgeons developed expected
surgical procedures according to preoperative evaluation
together and performed the final operative procedures.
Surgical procedures were classified as sphincter-preserving
radical excision, non-sphincter-preserving radical excision,
and palliative colostomy. In nearly all the cases, surgery
was performed within a week. Resected specimens were
examined by pathologists without knowing the preoperative
findings. The pathological findings were assessed accord-
ing to TNM classification of colorectal cancer, 6th edition,
by American Joint Committee on Cancer [16].
The primary endpoints were the accuracy of preoperative
staging and concordance rate of expected surgical proce-
dures. The secondary endpoint was association between
final surgical procedures and clinicopathological factors.
The clinicopathological factors included tumor height,
general category, texture of tumor, histology, differentia-
tion, pT stage, pN stage, pM stage, pTNM stage, and
preoperative serum levels of SAA.
Statistical analysis was performed by using the SPSS®
version 17.0 (SPSS, Chicago, IL, USA). Continuous
variables and percentages were compared between groups
by using the Mann–Whitney test or chi-square test,
respectively. Additionally, the Spearman test for univariate
analysis was performed. P=0.05 (two-sided) was consid-
ered as the limit of significance.
This study is registered as an International Standard
RandomisedControlled Trial, number ChiCTR-DT-00000409.
Results
From July 2008 to March 2009, 225 patients were
randomized. Seven patients were excluded after randomi-
zation because of neoadjuvant chemotherapy (n=5) and
hospital infections before surgery (n=2). The baseline
characteristics relating to the remaining 218 patients
(71 in Arm A, 72 in Arm B, and 72 in Arm C) are shown
in Table 2. The three arms were generally well-matched in
all terms. Figure 1 shows the trial profile.
Tables 3, 4, and 5 present the agreement of preoperative
staging and pathological staging in three arms. Regarding
Table 1 The preoperative staging standards of three arms
Preoperative
TNM stage
Arm A (MPE) Arm B (MSCT and SAA) Arm C (MSCT)
T stage
T1 Submucosa was irregularly thinned by a
hypoechoic tumor mass showed by TRUS
Intraluminal polypoid mass without thickening
of the bowel wall showed by MSCT
Intraluminal polypoid mass
without thickening of the bowel
wall showed by MSCT
T2 Complete disruption of submucosa, often
with thickening of the muscularis propria
showed by TRUS
T3 The border between the muscularis propria and
serosa or perirectal fat was irregular or
serrated showed by TRUS
Thickening of the bowel wall (>0.5 cm)
without invasion of surrounding tissue
showed by MSCT
Thickening of the bowel wall
(>0.5 cm) without invasion of
surrounding tissue showed by
MSCT
T4 Extension to the adjacent structures or organs
showed by TRUS
Invasion of surrounding tissue walls showed
by MSCT
Invasion of surrounding tissue
walls showed by MSCT
N stage
N0 No visible lymph node, or a lymph node
(diameter <8 mm) showed by MSCT with
SAA level <3.30 mg/L
No visible lymph node, or a lymph node
(diameter <8 mm) showed by MSCT with
SAA level <3.30 mg/L
No visible lymph node, or a
lymph node (diameter <8 mm)
showed by MSCT
N1 1. A lymph node (diameter <8 mm) showed
by MSCT but SAA level ≥3.30 mg/L; 2.
serum SAA level ≥8.90 mg/L; and 3. a
lymph node (diameter ≥8 mm) was
measured by MSCT
1. A lymph node (diameter <8 mm) showed
by MSCT but SAA level ≥3.30 mg/L; 2.
serum SAA level ≥8.90 mg/L; and 3. a
lymph node (diameter ≥8 mm) was
measured by MSCT
A lymph node (diameter
≥8 mm) was measured by
MSCT
M stage
M0 No distant metastases were found by MSCT No distant metastases were found by MSCT No distant metastases were found
by MSCT
M1 Distant metastases were found by MSCT Distant metastases were found by MSCT Distant metastases were found by
MSCT
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depth of tumor invasion (Table 3), the overall accuracy was
94.6% (70/74) in arm A, 77.8% (56/72) in arm B, and
80.6% (58/72) in arm C. The analysis showed that MPE
had a significantly higher accuracy of T staging than other
preoperative evaluation strategies in arm B (P=0.003) and
C (P=0.010). With regard to lymph nodes metastasis
(Table 4), the accuracy, sensitivity, and specificity were
85.1% (63/74), 90.2% (37/41), and 78.8% (26/33) in arm
A, 84.7% (61/72), 85.7% (36/42), and 83.3% (25/30) in
arm B, and 69.4% (50/72), 54.3% (19/35), and 83.8% (31/
37) in arm C, respectively. The analysis indicated that the
accuracy of preoperative N staging was significantly
different between arm A and C (P=0.023) and arm A and
B (P=0.029). Moreover, the incorporation of SAA into
MSCT led to significantly higher sensitivity (arm A vs. C,
P<0.001; arm B vs. C, P=0.002), while lower specificity
led to slight sensitivity (arm A vs. C, P=0.592; arm B vs.
C, P=0.961). All those patients with distant metastasis were
diagnosed correctly, and the accuracy of preoperative M
staging was 100% in three arms (Table 4). As for overall
preoperative TNM staging (Table 5), the accuracy of arm A
was 82.4% (61/74), and this did not differ significantly
from the figures obtained from arm B and C (81.9% and
70.8%, respectively, P>0.05).
Table 6 presents the agreement of expected surgical
procedures preoperatively and final surgical procedures
postoperatively in three arms. The concordance rate with
final surgical procedures was 95.9% (71/74) in arm A,
88.9% (64/72) in arm B, and 80.6% (58/72) in arm C. The
analysis showed that MPE was significantly superior to
preoperative MSCT evaluation strategy in prediction of
surgical procedures (P=0.001). No statistical difference was
observed in the prediction of surgical procedures between
arm A and B or arm B and C.
Table 7 presents that pathological T stage (P<0.001), N
stage (P<0.001), TNM stage (P<0.001), serum level of
SAA (P=0.002), and tumor height (P=0.030) were signif-
icantly associated with final surgical procedures. However,
all the correlation coefficient was small. No significant
association was found between final surgical procedure and
general category, texture of tumor, histology, differentia-
tion, or pM stage (P>0.05).
Discussion
The results of this trial demonstrate that MPE is an effective
strategy in preoperative staging and is more accurate than
Baseline characteristics Arm A Arm B Arm C P value
n 74 72 72
Male 51 (68.9) 47 (65.3) 40 (55.6) 0.230
Female 23 (31.1) 25 (34.7) 32 (44.4)
Age (years) 59 (30–80) 60.5 (22–81) 60 (28–80) 0.543
Tumor height (cm) 5 (1–9) 7 (1–10) 6 (1–11) 0.070
Pathological TNM stage
I 11 (14.9) 8 (11.1) 21 (29.2) 0.118
II 20 (27.0) 22 (30.6) 14 (19.4)
III 34 (45.9) 36 (50.0) 31 (43.1)
IV 9 (12.2) 6 (8.3) 6 (8.3)
Table 2 Baseline characteristics
of three arms
a Data are medians with ranges
in parentheses or numbers with
percentages in parentheses.
Fig. 1 Trial profile
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other available strategies in surgical decision making for
rectal cancer. TRUS was successfully used to assess local
infiltration in MPE system and led to a significantly higher
concordance rate of 94.6% than MSCT. The strategy
combining MSCT with SAA to identify metastatic lymph
nodes in MPE system led to higher accuracy of 85.1%.
Although MPE system is reported to have a non-significant
increase of overall TNM staging with an accuracy of
82.4%, this multimodal strategy provides the most accurate
preoperative staging and effectively guides surgical deci-
sion making. However, we should draw this conclusion
with a caution, due to the use of MSCT, not MRI, in this
study. Many Chinese patients cannot afford the expensive
cost of MRI examination, although increasing evidence
show MRI is more superior on local invasion [17–19].
Thus, in this study, we use MSCT instead. The result shows
MPE system based on MSCT is effective and affordable to
patients in developing countries. The role of MRI in MPE
system should be warranted in the future.
Our preoperative T staging finding supports the reported
studies of TRUS superior toMSCT in local infiltration. TRUS
is the most established and preferred modality for T-staging of
rectal cancer with an accuracy of 64–96% [20, 21]. In
comparison, even when optimized with rectal contrast,
glucagon, and prone thin-slice imaging, CT is still limited
for local staging because of its inherent low soft tissue
contrast. This does not allow for accurate approximation of
T stage unless there is gross invasion of adjacent organs
[22]. Although no widely accepted protocol has been
reached on the role of diagnostic imaging in the preoperative
T staging of rectal cancer, an increasing volume of controlled
studies [23–26] and two meta-analysis [7, 8] appear that
TRUS provides a more accurate information for local
invasion. That is the reason why TRUS is adopted for local
staging in the MPE system. However, there is still some
space for T staging improvements by 3-D TRUS or biopsy,
after TRUS [23, 27].
The novel strategy which combined MSCT with SAA
serves as a potential approach to improve the assessment of
metastatic lymph nodes. Evaluation of lymph node
involvement is a difficult task for radiologists. A node
measuring more than 8 mm in the short axis is probably
malignant [28]. However, enlarged nodes may be benign
and reactive, whereas small nodes may be infiltrated. For
rectal cancer, in particular, over half of the metastatic nodes
are less than 5 mm, which makes sense in the difficulty to
evaluate lymph node involvement [29, 30]. There is a wide
variation in accuracy for metastatic nodal detection with
TRUS (62–87%), CT (22–73%), and MRI (39–75%) [9].
Thus, current imaging techniques are comparably low in
accuracy for lymph nodes staging. The main limitations are
the use of size criteria, overstaging in inflammatory
enlargement, and understaging in nodes beyond the range
of image. Recently at the authors’ institution, a novel
strategy combining MSCT (or TRUS) with SAA was
documented to identify inflammatory enlargement from
lymph node involvement or detect the "invisible" metastatic
lymph nodes by imaging since the preoperative levels of
inflammatory cytokines were considered to associate with
metastatic lymph nodes [12, 13, 31]. These previous studies
demonstrated that the combination of MSCT with SAA or
TRUS with SAA can improve the accuracy of N staging
from 62.9-86.5% or 57.7-77.8%, respectively. Similar result
was observed in colonic cancer [32]. For the reason that
SAA, incorporated into MSCT staging, makes more small
metastatic lymph nodes diagnosed correctly, which means
MSCT plus SAA leads to higher sensitivity with acceptably
decreased specificity. In this study, MSCT combined with
SAA is demonstrated to be effective in N staging
Arm A Arm B Arm C
T stage preT1 preT2 preT3 preT4 preT1–2 preT3 preT4 preT1–2 preT3 preT4
pT1 4 0 0 0 1 0 0 4 2 0
pT2 0 8 1 0 5 2 0 13 3 0
pT3 0 1 9 1 1 7 3 0 5 0
pT4 0 0 1 49 0 10 43 0 9 36
n 4 9 11 50 7 19 46 17 19 36
Table 3 Preoperative vs. patho-
logical T staging in three arms
Table 4 Preoperative vs. pathological N and M staging in three arms
Arm A Arm B Arm C
N stage preN0 preN1 preN0 preN1 preN0 preN1
pN0 26 7 25 5 31 6
pN1–2 4 37 6 36 16 19
n 30 44 31 41 47 25
M stage preM0 preM1 preM0 preM1 preM0 preM1
pM0 65 0 66 0 66 0
pM1 0 9 0 6 0 6
n 65 9 66 6 66 6
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assessment again. However, we should only draw a
cautious conclusion on this innovative method. Since
SAA is not considered as a cancer-specific marker and
an increased concentration is associated with a broad
spectrum of diseases, stricter eligibility should be
developed to promote the MPE system stability [33].
Moreover, other acute-phase proteins associated with
metastatic lymph nodes, e.g., C-reactive protein and
fibrinogen, highlight that future trials may try to compare
them with SAA and determine the best one for MPE
system [12, 34].
The MPE strategy led to a significantly increased concor-
dance rate of prediction in surgical procedures for rectal
cancer as compared with MSCT alone (95.9% vs. 80.6%, P=
0.001). The additional analysis of this study may explain the
role of preoperative staging in improving surgical decision
making. Firstly, the result indicates that tumor height remains
one of the primary factors that influence the choice of
surgical management, provided by TRUS accurately in MPE
system. With application on the current concept of concise
continent resection, combined with total extirpation of the
mesorectum, tumors of the upper and middle third of the
rectum can be easily resected with preservation of sphincter.
In tumors of the lower third, sphincter is preserved in most
cases. The only exceptions are patients in whom the
sphincter itself is affected or in whom a distal margin of
less than 1 cm cannot be achieved [35]. Secondly, the local
infiltration and advances, i.e., T stage, are associated with
surgical procedures performed. About 15% rectal cancer
involves the uterus, adnexa, posterior vaginal wall, and
bladder [36, 37], which can be well-evaluated by TRUS in
MPE system. En bloc resection is an aggressive surgical
method to manage locally advanced, adherent colorectal
tumors in order to achieve a complete resection for lesions
that are staged T4 clinically and pathologically [38].
Considering the high incidence of complication, low quality
of life, and improved adjuvant therapy efficacy, the palliative
colostomy followed by postoperative adjuvant therapy was
performed instead in the authors’ institution. Other clinico-
pathological factors, i.e., N stage, TNM stage, and SAA
levels, should be indirectly associated with surgical decision
making. High grade of these factors always reflects the local
advanced rectal cancer. Therefore, those factors mentioned
above provided accurately by MPE system allow for
tailoring more appropriate surgical decision making in rectal
cancer. Besides, it should be noticed that the surgeon’s
expertise also plays a crucial role in surgical options [39].
Conclusion
In this study, MPE system is a more effective strategy than
a single-imaging technique in preoperative assessment of
the depth of infiltration and metastatic lymph nodes of
rectal cancers. In the MPE system, TRUS is successfully
used to stage local invasion, whilst MSCT combined with
SAA are proven to precisely evaluate lymph node involve-
ment. More importantly, it is a useful aid in the surgical
Table 6 Expected surgical procedures preoperatively and final
surgical procedures postoperatively in three arms
Expected surgical procedures n Final surgical procedures
SPR NSPR PC
Arm A
SPR 58 55 2 1
NSPR 6 0 6 0
PE 10 0 0 10
n 74 55 8 11
Arm B
SPR 57 51 3 3
NSPR 4 2 2 0
PE 11 0 0 11
n 72 53 5 14
Arm C
SPR 50 46 2 2
NSPR 14 5 5 4
PE 8 0 1 7
n 72 51 8 13
SPR sphincter-preserving radical excision, NSPR non-sphincter-
preserving radical excision, and PC palliative colostomy
Table 5 Preoperative vs. pathological TNM classification in three arms
Arm A Arm B Arm C
TNM stage preI preII preIII preIV preI preII preIII preIV preI preII preIII preIV
pI 8 1 2 0 4 1 3 0 17 1 3 0
pII 1 14 5 0 1 19 2 0 0 11 3 0
pIII 1 3 30 0 0 6 30 0 0 14 17 0
pIV 0 0 0 9 0 0 0 6 0 0 0 6
n 10 18 37 9 5 26 35 6 17 26 23 6
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decision making of these patients mainly based on
improved preoperative staging. MPE strategy could provide
reliable information on pathological T, N, TNM stages,
SAA levels, and tumor height which allow for appropriate
stage-specific preoperative therapy and prediction of surgi-
cal procedures.
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Table 7 The relationship between final operative procedures and clinicopathological factors
Clinicopathological factors SPR NSPR PC Correlation coefficient P value
n 159 21 38
Tumor height (cm) 6.26±2.62 4.76±2.68 4.54±2.69 −0.147 0.030
General category −0.070 0.305
Protrude type 51 (32.1) 7 (33.3) 19 (50.0)
Ulcer type 95 (59.7) 12 (57.1) 13 (34.2)
Infiltrating type 10 (6.3) 1 (4.8) 4 (10.5)
Other type 3 (1.9) 1 (4.8) 2 (5.3)
Texture of tumor 0.066 0.329
Rigid 108 (67.9) 12 (57.1) 31(81.6)
Moderate 43 (27.0) 6 (28.6) 7 (18.4)
Soft 8 (5.1) 3 (14.3) 0
Histology 0.086 0.204
Adenocarcinoma 134 (84.3) 19 (90.4) 33 (86.8)
Mucous adenocarcinoma 17 (10.7) 1 (4.8) 2 (5.3)
Signet ring cell carcinoma 2 (1.2) 0 2 (5.3)
Others 6 (3.8) 1 (4.8) 1 (2.6)
Differentiation −0.034 0.621
Well-differentiated 1 (0.6) 0 0
Moderately differentiated 111 (69.8) 16 (76.2) 29 (76.3)
Poorly differentiated 38 (23.9) 4 (19.0) 4(10.5)
Others 9 (5.7) 1(4.8) 5 (13.2)
pT 0.297 <0.001
pT1 11 (6.9) 0 0
pT2 32 (20.1) 0 0
pT3 20 (12.6) 5 (23.8) 2 (5.3)
pT4 96 (60.4) 16 (76.2) 36 (94.7)
pN 0.234 <0.001
pN0 84 (52.8) 7 (33.3) 9 (23.7)
pN1 75 (47.2) 14 (66.7) 29 (76.3)
pM 0.097 0.152
pM0 146 (91.8) 20 (95.2) 31 (81.6)
pM1 13 (8.2) 1 (4.8) 7 (18.4)
pTNM 0.290 <0.001
I 40 (25.2) 0 0(0)
II 42 (26.4) 7 (33.3) 7 (18.4)
III 64 (40.3) 13 (61.9) 24 (63.2)
IV 13 (8.1) 1 (4.8) 7 (18.4)
Serum levels of SAA(mg/L)b 8.40±13.84 19.37±45.84 51.46±130.34 0.252 0.002
SPR sphincter-preserving radical excision, NSPR non-sphincter-preserving radical excision, PC palliative colostomy
a Data are numbers with percentages in parentheses
b Only the data of MPE and MSCT+SAA groups were pooled into analysis
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